Henry A Adeola, Jonathan M Blackburn, Timothy R Rebbeck, Luiz F Zerbini
First published: 25 Mar 2017
PMID: 28388542 PMCID: PMC5514967 DOI: 10.18632/oncotarget.16568
Various biomarkers have emerged via high throughput omics-based approaches for use in diagnosis, treatment, and monitoring of prostate cancer. Many of these have yet to be demonstrated as having value in routine clinical practice. Moreover, there is a dearth of information on validation of these emerging prostate biomarkers within African cohorts, despite the huge burden and aggressiveness of prostate cancer in men of African descent. This review focusses of the global landmark achievements in prostate cancer proteomics biomarker discovery and the potential for clinical implementation of these biomarkers in Africa. Biomarker validation processes at the preclinical, translational and clinical research level are discussed here, as are the challenges and prospects for the evaluation and use of novel proteomic prostate cancer biomarkers.
Keywords: Africa; biomarker; mass spectrometer; prostate cancer; proteomics.
Full text: 10.18632/oncotarget.16568
Please contact us if you are having difficulty accessing the full PDF of this or any MADCaP publication.